Pay in 4 interest-free payments of $5.71 Learn more
Ships within 48 hours · Estimated delivery Sep 11 - Sep 16
Study: Triple-Hormone-Receptor Agonist Retatrutide for Obesity Journal: New England Journal of Medicine (NEJM) ClinicalTrials ID: NCT04881760 View Full Study Retatrutide is a glucagon, GLP-1, and GIP (triple hormone) receptor agonist being investigated to treat obesity
Hypoglycaemia : People with type 2 diabetes taking insulin or sulphonylureas alongside GLP-1-based therapies require careful monitoring due to an increased risk of hypoglycaemia
Staying well-hydrated when drinking becomes even more critical given dehydration risks with this medication class
Procurement and PI sign-offs can pull historical lot data directly from the page, which makes audit trails easier to build before a purchase order goes out
Ongoing post-marketing surveillance and long-term clinical trials are crucial to understanding the broader implications of its use over time, particularly concerning the management of chronic conditions like IBS, diabetes, and obesity
PubMed: 12750433 TB-4 wound healing dermal repair acceleration with TB-4 in wound models: Malinda KM et al
US$ 22.66
US$ 28.27
US$ 26.28
US$ 20.42
US$ 23.85
US$ 27.65
US$ 27.23
US$ 23.19
US$ 22.60
US$ 24.91
